The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies

This study provides Class IV evidence that for a patient with relapsed anti-MAG antibody polyneuropathy, MYD88 wild-type, venetoclax plus rituximab is effective.

Source: Neurology Neuroimmunology and Neuroinflammation - July 7, 2022 Category: Neurology Authors: Briani, C., Visentin, A., Castellani, F., Cacciavillani, M., Trentin, L. Tags: All Clinical Neurology, Peripheral neuropathy, Class IV Clinical/Scientific Note Source Type: research